Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS

7/27/2015

0 Comments

 
Kenilworth, NJ - Merck, known as MSD outside the United States and Canada, announced today that the company's commitment to HIV and AIDS, which started with a research and development program initiated in the mid-1980s during the early years of the epidemic, is now entering its fourth decade. To commemorate Merck's 30 years of commitment in this area, the company is launching a new effort, “Positively Committed.” The campaign highlights the company’s contributions, including the development of innovative therapies to address the unmet medical needs of people infected with HIV-1.
“The global health community has made significant progress in the fight against HIV and Merck is proud of our role in this fight, starting at the outset of the epidemic, and continuing to this day,” said Daria J. Hazuda, vice president and therapeutic area head, infectious disease and vaccines. “Although antiretroviral therapy has advanced the management of HIV-1, much work remains to be done. We will continue to collaborate with scientists, clinicians, patient advocates and the global health community as we work together towards a common goal of eradicating this disease.”

Legacy of Commitment

  • In the mid-1980s, soon after the public health community first coined the term “AIDS” to describe this emerging epidemic, Merck began its HIV/AIDS research. Merck researchers were the first to describe the chemical structure of the protease enzyme, and published the findings immediately to encourage further research efforts. Merck researchers then developed CRIXIVAN® (indinavir sulfate), an HIV protease inhibitor, which was approved by the European Medicines Agency and the U.S. Food and Drug Administration (FDA) in 1996. At the time, the FDA's approval of CRIXIVAN (indinavir sulfate) was the fastest approval in FDA history.
  • In 1997, Merck's clinical study of CRIXIVAN was the first to show that a combination of antiretroviral medicines could provide prolonged suppression of HIV RNA. Today, CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection.
  • In 1999, Merck introduced efavirenz, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), which was developed by Merck and DuPont Pharmaceuticals. Merck retained the rights to market efavirenz in select markets outside the U.S. Today, efavirenz is one of the most commonly prescribed antiretroviral therapies worldwide.
  • In the early 1990s, Merck was the first to demonstrate that inhibition of the HIV-1 integrase enzyme—which is required for HIV replication—was possible, and that inhibiting the integrase protein reduced replication and spread of the virus. This research advancement led to the development of ISENTRESS® (raltegravir). In 2007, the approval of ISENTRESS introduced a new class of treatments, HIV-1 integrase strand transfer inhibitors. Today, ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response.
In addition, since the mid-1980s shortly after the HIV virus was identified, Merck pursued one of the largest HIV vaccine research programs, culminating in a large-scale trial that illustrated the difficulty of developing a successful HIV vaccine.

Merck's research efforts today include programs to develop novel HIV treatment and prevention technologies, and collaborations on approaches to address HIV latency and eradication.

Research is only one part of our comprehensive strategy to address unmet needs in HIV. Merck also has sought to increase access to our HIV medicines, particularly in resource limited settings.

“Effective treatments for HIV-1 infection were a distant hope in the 1980s, but collaborative scientific discovery and effective advocacy have made them possible today," said Dr. Julie Gerberding, executive vice president, strategic communications, global public policy, and population health at Merck. “I'm proud that Merck is committed to sustaining our contributions to the treatment of this infection around the world.”

Addressing the Challenge of HIV/AIDS through Collaboration

Since the inception of its HIV/AIDS research program 30 years ago, Merck has recognized the global impact of HIV/AIDS in developing countries where economic, social and political factors impede access to education, care and treatment. The Merck Foundation has partnered with governments, non-governmental organizations and various other stakeholders, contributing more than $122 million over the past 15 years to support intervention programs, strengthen healthcare capacity and improve access to treatment. In addition, Merck has provided access strategies, such as differential pricing and voluntary licensing, to enhance access to treatment in these communities.

This year, Merck partnered with the Medicines Patent Pool to provide access to raltegravir for infants and children from four weeks to under 12 years of age in low- and middle-income developing countries.

 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619